MiNK Therapeutics Announces Publication of Complete Remission Following Allogeneic iNKT Cell Therapy in Metastatic Testicular Cancer
MiNK Therapeutics (NASDAQ: INKT) announced a groundbreaking publication in Nature's Oncogene detailing a complete remission case in metastatic testicular cancer using their agenT-797 allogeneic iNKT cell therapy. The patient, who had previously failed multiple treatments including platinum-based chemotherapy and immunotherapies, achieved complete remission lasting over two years after a single infusion of agenT-797 with nivolumab.
The therapy demonstrated remarkable safety with no cytokine release syndrome or graft-versus-host disease. Additionally, MiNK presented promising Phase 2 trial data in gastric cancer showing extended survival beyond 12 months in several patients, with a separate case reporting 42% tumor reduction and nine months progression-free survival.
MiNK Therapeutics (NASDAQ: INKT) ha annunciato una pubblicazione rivoluzionaria su Nature's Oncogene che descrive un caso di remissione completa in un tumore testicolare metastatico grazie alla loro terapia con cellule iNKT allogeniche agenT-797. Il paziente, che aveva precedentemente fallito diversi trattamenti inclusa la chemioterapia a base di platino e immunoterapie, ha ottenuto una remissione completa durata oltre due anni dopo una singola infusione di agenT-797 associata a nivolumab.
La terapia ha mostrato un profilo di sicurezza eccezionale con assenza di sindrome da rilascio di citochine e malattia del trapianto contro l’ospite. Inoltre, MiNK ha presentato dati promettenti della Fase 2 in tumore gastrico, evidenziando una sopravvivenza prolungata oltre i 12 mesi in diversi pazienti, con un caso separato che ha riportato una riduzione del tumore del 42% e una sopravvivenza libera da progressione di nove mesi.
MiNK Therapeutics (NASDAQ: INKT) anunció una publicación innovadora en Nature's Oncogene que detalla un caso de remisión completa en cáncer testicular metastásico utilizando su terapia celular iNKT alogénica agenT-797. El paciente, que previamente había fracasado en múltiples tratamientos, incluyendo quimioterapia basada en platino e inmunoterapias, logró una remisión completa que duró más de dos años tras una única infusión de agenT-797 junto con nivolumab.
La terapia demostró una seguridad notable sin síndrome de liberación de citocinas ni enfermedad injerto contra huésped. Además, MiNK presentó datos prometedores del ensayo de Fase 2 en cáncer gástrico, mostrando una supervivencia prolongada más allá de los 12 meses en varios pacientes, con un caso separado que reportó una reducción tumoral del 42% y nueve meses de supervivencia libre de progresión.
MiNK Therapeutics (NASDAQ: INKT)는 Nature's Oncogene에 전이성 고환암에서 agenT-797 동종 iNKT 세포 치료제를 사용한 완전 관해 사례를 상세히 다룬 획기적인 논문을 발표했습니다. 이전에 백금 기반 화학요법과 면역치료를 포함한 여러 치료에 실패한 환자가 agenT-797과 니볼루맙의 단일 주입 후 2년 이상 지속되는 완전 관해를 달성했습니다.
이 치료법은 사이토카인 방출 증후군이나 이식편대숙주병 없이 뛰어난 안전성을 입증했습니다. 또한 MiNK는 위암에서 2상 임상시험 데이터를 발표했으며, 여러 환자에서 12개월 이상의 생존 연장과 별도의 사례에서 42% 종양 감소 및 9개월 무진행 생존을 보고했습니다.
MiNK Therapeutics (NASDAQ : INKT) a annoncé une publication révolutionnaire dans Nature's Oncogene, détaillant un cas de rémission complète d’un cancer testiculaire métastatique grâce à leur thérapie cellulaire iNKT allogénique agenT-797. Le patient, qui avait précédemment échoué à plusieurs traitements, y compris la chimiothérapie à base de platine et des immunothérapies, a obtenu une rémission complète durant plus de deux ans après une seule perfusion d’agenT-797 associée au nivolumab.
La thérapie a démontré une sécurité remarquable, sans syndrome de libération de cytokines ni maladie du greffon contre l’hôte. De plus, MiNK a présenté des données prometteuses de l’essai de phase 2 dans le cancer gastrique, montrant une survie prolongée au-delà de 12 mois chez plusieurs patients, avec un cas distinct rapportant une réduction tumorale de 42 % et neuf mois de survie sans progression.
MiNK Therapeutics (NASDAQ: INKT) gab eine bahnbrechende Veröffentlichung in Nature's Oncogene bekannt, die einen Fall einer kompletten Remission bei metastasiertem Hodenkrebs mit ihrer agenT-797 allogenen iNKT-Zelltherapie beschreibt. Der Patient, der zuvor mehrere Behandlungen einschließlich platinhaltiger Chemotherapie und Immuntherapien nicht erfolgreich durchlaufen hatte, erreichte nach einer einzigen Infusion von agenT-797 zusammen mit Nivolumab eine vollständige Remission, die über zwei Jahre anhielt.
Die Therapie zeigte eine bemerkenswerte Sicherheit ohne Zytokinfreisetzungssyndrom oder Graft-versus-Host-Erkrankung. Zusätzlich präsentierte MiNK vielversprechende Daten aus der Phase-2-Studie bei Magenkrebs, die eine Überlebensverlängerung von über 12 Monaten bei mehreren Patienten zeigten, sowie einen separaten Fall mit 42% Tumorreduktion und neun Monaten progressionsfreiem Überleben.
- None.
- None.
Insights
MiNK's iNKT cell therapy shows remarkable complete remission in refractory metastatic testicular cancer with 2+ years durability.
This publication in Nature's Oncogene represents a potentially significant breakthrough in solid tumor immunotherapy. The case documents a complete and durable remission lasting over two years in a patient with metastatic testicular cancer who had exhausted all standard treatment options including platinum chemotherapy, stem cell transplant, and multiple checkpoint inhibitors.
What makes this particularly notable is that complete remissions in heavily pretreated, checkpoint inhibitor-resistant metastatic solid tumors are exceedingly rare. The patient received just a single infusion of agenT-797 (MiNK's allogeneic iNKT cell therapy) alongside nivolumab, with donor cells remaining detectable for six months post-infusion.
The safety profile appears remarkably clean - no cytokine release syndrome or graft-versus-host disease was observed. This addresses two major concerns with cell therapies, particularly allogeneic (donor-derived) approaches. The absence of these complications suggests potential for outpatient administration without the intensive monitoring requirements of CAR-T therapies.
This case adds to MiNK's emerging clinical evidence portfolio, including their Phase 2 gastric cancer data showing immune activation and tumor control in checkpoint-refractory patients. The persistence of donor cells for six months may explain the durability of response, suggesting these cells effectively reshape the tumor microenvironment to overcome prior treatment resistance.
While a single case cannot establish efficacy across broader populations, this complete remission in such a challenging context provides compelling rationale for expanded clinical development of iNKT cell therapies in solid tumors where treatment options remain limited.
New report adds to growing evidence of iNKT cell therapy’s potential in solid tumors
NEW YORK, July 11, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today announced the publication of another landmark case in Nature’s Oncogene describing a complete and durable remission in a patient with metastatic, treatment-refractory testicular cancer, following treatment with agenT-797, MiNK’s allogeneic iNKT cell therapy.
Complete remission after failure on platinum-based chemotherapy, autologous stem cell transplant, and multiple ICIs (anti–PD-1, anti–CTLA-4, and anti–TIGIT)
The publication, titled “Salvage therapy with allogeneic invariant natural killer T cells in a heavily pre-treated germ cell tumor,” presents a patient case from MiNK’s clinical trial (NCT05108623). The patient had progressed after multiple lines of therapy—including platinum-based chemotherapy, autologous stem cell transplant, and multiple immune checkpoint inhibitors (anti–PD-1, anti–CTLA-4, and anti–TIGIT)—and received a single infusion of agenT-797 alongside nivolumab. The patient achieved a complete clinical, radiologic, and biochemical remission, with no evidence of disease over two years later. Donor iNKT cells were detectable up to six months post-infusion, and treatment was well-tolerated with no cytokine release syndrome (CRS) or graft-versus-host disease (GVHD).
“This case exemplifies the powerful potential of iNKT cells in treating even the most challenging cancers,” said Dr. Benjamin Garmezy, Assistant Director of Genitourinary Research for Sarah Cannon Research Institute at SCRI Oncology Partners. “We observed a remarkable response in a patient who had exhausted standard and experimental treatments, offering compelling evidence to further pursue clinical studies of iNKT cell therapies in solid tumors.”
Durable Responses & Immune Activation in Solid Tumors with Allo-iNKT Therapy
These findings are part of a growing body of clinical evidence supporting the potential of agenT-797 in solid tumors. At the 2025 inaugural AACR Immuno-Oncology meeting, MiNK presented data from its Phase 2 trial in 2L gastric cancer, demonstrating immune activation, increased tumor infiltration, and early signals of tumor control in patients previously refractory to checkpoint inhibitors. Notably, extended survival beyond 12 months was observed in several patients—an outcome rarely seen in this setting. These clinical observations were further reinforced in a separate peer-reviewed case report published in Oncogene, which described a patient with metastatic gastric cancer who achieved a
Together, these data highlight the potential of agenT-797 to reshape the tumor microenvironment and deliver durable clinical activity, even in heavily pretreated, immunotherapy-resistant cancers. The ongoing Phase 2 trial in gastric cancer (NCT06251973) is actively enrolling, with additional readouts expected in upcoming months. You can access the full publication here.
About MiNK Therapeutics
MiNK Therapeutics is a clinical-stage biopharmaceutical company advancing a new class of allogeneic invariant natural killer T (iNKT) cell therapies and precision-targeted immune technologies. MiNK’s proprietary platform is designed to restore immune balance and drive cytotoxic responses across cancer, immune-mediated diseases, and pulmonary immune failure. The company’s lead candidate, agenT-797, is an off-the-shelf, cryopreserved iNKT cell therapy currently in clinical development for graft-versus-host disease (GvHD), solid tumors, and severe pulmonary inflammation. MiNK is also advancing a pipeline of T cell receptor (TCR)-based therapies and neoantigen discovery tools that enable highly specific immune targeting across tumor and tissue types. With a scalable manufacturing process and a differentiated mechanism that bridges innate and adaptive immunity, MiNK is committed to delivering accessible, durable, and broadly applicable immune reconstitution therapies. For more information, visit www.minktherapeutics.com or follow us on X @MiNK_iNKT. Information important to investors is routinely posted to our website and social media channels.
About AgenT-797
AgenT-797 is an allogeneic invariant natural killer T (iNKT) cell therapy that harnesses the dual power of innate and adaptive immunity. iNKTs function as “master regulators,” combining the cytotoxic capabilities of NK cells with T-cell–like antigen recognition and memory. This unique biology enables a robust, pathogen-agnostic immune response that can be directed against hard-to-treat tumors.
Manufactured by MiNK Therapeutics in Lexington, MA, agenT-797 is a scalable, off-the-shelf product designed to provide accessible, transformative treatment options. In clinical trials, agenT-797 can bolster peripheral memory T-cell activation, enhance tumor infiltration, and potentially improve outcomes for patients with solid cancers (Cytryn et al., AACR IO 2024; Oncogene, 2024), as well as reduce inflammation in critically ill patients with severe respiratory pathology (Nature Communications, 2024).
Forward Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the therapeutic potential, anticipated benefit, plans and timelines of iNKT cells. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These forward-looking statements are subject to risks and uncertainties, including the factors described under the Risk Factors section of the most recent Form 10-K, Form 10-Q and the S-1 Registration Statement filed with the SEC. MiNK cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and MiNK and Agenus with no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.
Investor Contact 917-362-1370 investor@minktherapeutics.com Media Contact 781-674-4428 communications@minktherapeutics.com
FAQ
What results did MiNK Therapeutics (INKT) achieve in their testicular cancer trial?
How safe is MiNK Therapeutics' agenT-797 treatment?
What are the latest Phase 2 trial results for INKT's gastric cancer treatment?
How effective was agenT-797 in treating gastric cancer patients?
What types of previous treatments had the testicular cancer patient failed before trying agenT-797?
